Clinical Trial List | New Mexico Cancer Care Alliance

Type of Cancer
Clinical Trial Site

Last updated on Thursday, 27 February 2020

Christus St Vincent Regional Cancer Center

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-03	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2017-01-24	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1415CD	CCDR	Open Active	2017-06-07	SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-12-09	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401	Supportive	Open Active	2016-09-29	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
WFU WF 97115	Supportive	Open Active	2018-10-31	WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer

Lovelace Medical Center-Saint Joseph Square

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-19	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-01-31	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1706	Breast Neoadjuvant	Open Active	2019-06-24	SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2019-04-05	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Alliance A021502	GI Colorectal Adjuvant	Open Active	2018-10-12	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S0820	GI Colorectal Prevention	Open Active	2018-07-27	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
ECOG-ACRIN EA2165	GI Other	Open Active	2019-04-15	ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
SWOG S1815	GI Other	Open Active	2019-12-27	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
INST 96144	Ill Defined	Open Active	2015-07-28	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-05-12	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-04-09	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-04-09	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400F	Lung SCLC Advanced	Open Active	2019-11-06	SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1616	Skin Melanoma Advanced	Open Active	2019-07-02	SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Alliance A011401	Supportive	Open Active	2016-09-17	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001A	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001B	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001C	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001D	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********

Lovelace Radiation Oncology

Trial #	Type	Study Status	Status Date	Title
NSABP B-51	Breast Adjuvant	Open Active	2017-04-13	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A221505	Breast Advanced	Open Active	2018-04-10	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-10-10	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706	Breast Neoadjuvant	Open Active	2019-06-24	SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806	Breast Other	Open Active	2019-03-14	INST LWH 1806: TARGIT New Mexico
ECOG-ACRIN EA2165	GI Other	Open Active	2019-04-15	ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NRG Oncology NRG-GU005	GU Prostate Advanced	Open Active	2018-02-21	NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
GOG 0263	GYN Cervical Adjuvant	Open Active	2017-06-02	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724	GYN Cervical Adjuvant	Open Active	2017-06-07	RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
WFU WF-1801	Supportive	Open Active	2019-04-01	Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Lovelace Respiratory Research Institute

Trial #	Type	Study Status	Status Date	Title
LRRI #1054101	Lung Ancillary	Open Active	2001-03-01	LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #	Type	Study Status	Status Date	Title
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2019-04-05	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
INST LWH 1806	Breast Other	Open Active	2019-03-14	INST LWH 1806: TARGIT New Mexico
INST UNM CR1801	Multiple Sites	Open Active	2018-09-04	INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
Alliance A011401	Supportive	Open Active	2017-11-08	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Memorial Medical Center

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-04	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2017-01-26	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-01-31	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807	Breast Advanced	Open Active	2020-02-17	INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-08-21	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2019-03-27	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
NRG Oncology/SWOG NRG-GI004/SWOG-S1610	GI Colorectal Advanced	Open Active	2019-07-22	NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
SWOG S1815	GI Other	Open Active	2019-05-02	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
GOG 0263	GYN Cervical Adjuvant	Open Active	2011-02-07	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY005	GYN Other	Open Active	2019-06-24	NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN NHLBI-MDS	Hematology Other	Open Active	2017-03-27	ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
UNM 1709	Ill Defined	Open Active	2019-07-02	INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-04-21	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400F	Lung SCLC Advanced	Open Active	2019-11-06	SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Pharm ML28897/PRO 02	Solid Tumors Other	Open Active	2019-07-03	Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
Alliance A011401	Supportive	Open Active	2016-12-16	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001A	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001B	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001C	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001D	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
ECOG-ACRIN E1Q11	Supportive	Open Active	2018-04-18	ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship

New Mexico Oncology Hematology Consultants

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-04	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2016-10-20	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-01-31	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A221505	Breast Advanced	Open Active	2018-04-10	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-12-18	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-11-05	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S0820	GI Colorectal Prevention	Open Active	2018-09-14	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm PrTK03	GU Prostate Adjuvant	Open Active	2017-06-28	Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
Pharm PANC003	GI Pancreatic Advanced	Open Active	2019-12-17	Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
SWOG S1815	GI Other	Open Active	2019-05-13	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Alliance A021602	GI Other	Open Active	2019-05-08	Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Pharm INCB 18424-MA-GD-301	Hematology Stem Cell Transplant	Open Active	2019-01-29	Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
NRG Oncology NRG-HN004	Head And Neck Advanced	Open Active	2019-03-20	NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
ECOG-ACRIN EA3132	Head And Neck Adjuvant	Open Active	2016-10-26	ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NRG Oncology NRG-GU005	GU Prostate Advanced	Open Active	2018-01-29	NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-05-17	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
UNM 1709	Ill Defined	Open Active	2019-07-02	INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144	Ill Defined	Open Active	2014-12-09	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1400F	Lung SCLC Advanced	Open Active	2019-11-06	SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-04-17	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-04-17	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Pharm ML28897/PRO 02	Solid Tumors Other	Open Active	2020-02-18	Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations

NMOHC Gallup

Trial #	Type	Study Status	Status Date	Title
INST 96144	Ill Defined	Open Active	2018-06-18	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives

Presbyterian Medical Group

Trial #	Type	Study Status	Status Date	Title
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance A011502	Breast Adjuvant	Open Active	2017-05-08	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A171601	Breast Advanced	Open Active	2020-01-03	Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-01-31	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
SWOG S1815	GI Other	Open Active	2019-05-13	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S0820	GI Colorectal Prevention	Open Active	2017-11-29	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
NRG Oncology/SWOG NRG-GI004/SWOG-S1610	GI Colorectal Advanced	Open Active	2020-01-10	NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502	GI Colorectal Adjuvant	Open Active	2020-01-14	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1415CD	CCDR	Open Active	2017-06-07	SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144	Ill Defined	Open Active	2013-06-04	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Pharm CA209901	GU Other	Open Active	2019-06-11	Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Pharm PANC003	GI Pancreatic Advanced	Open Active	2019-07-22	Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-04-21	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Alliance A011401	Supportive	Open Active	2016-11-01	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Presbyterian Rust Medical Center

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2018-04-19	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A171601	Breast Advanced	Open Active	2020-01-03	Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-01-31	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1815	GI Other	Open Active	2019-04-30	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S0820	GI Colorectal Prevention	Open Active	2018-09-14	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
NRG Oncology/SWOG NRG-GI004/SWOG-S1610	GI Colorectal Advanced	Open Active	2020-01-14	NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502	GI Colorectal Adjuvant	Open Active	2020-01-14	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1415CD	CCDR	Open Active	2018-08-20	SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144	Ill Defined	Open Active	2018-04-10	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Pharm 4010-03-001	GYN Endometrial Advanced	Open Active	2020-02-12	Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
GOG 0263	GYN Cervical Adjuvant	Open Active	2018-06-07	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Pharm PANC003	GI Pancreatic Advanced	Open Active	2019-07-22	Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-04-05	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-04-05	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-08-04	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A011401	Supportive	Open Active	2018-04-19	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial

Southwest Gynecologic Oncology Associates

Trial #	Type	Study Status	Status Date	Title
NRG-GY018	GYN Endometrial Advanced	Open Active	2020-01-23	NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Pharm C-750-01/GOG-3028	GYN Cervical Advanced	Open Active	2020-02-13	Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
RTOG 0724/GOG-0724	GYN Cervical Adjuvant	Open Active	2015-10-30	RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263	GYN Cervical Adjuvant	Open Active	2010-12-02	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
UNM 1419	GYN Ovarian Advanced	Open Active	2019-06-04	INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
Pharm 3000-02-006	GYN Ovarian Advanced	Open Active	2020-02-06	Tesaro 3000-02-006: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
NRG Oncology NRG-GY007	GYN Ovarian Advanced	Open Active	2018-12-27	NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-0264	GYN Ovarian Advanced	Open Active	2011-04-21	GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
NRG Oncology NRG-GY005	GYN Other	Open Active	2019-11-06	NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
GOG 0238	GYN Uterine Advanced	Open Active	2015-08-24	GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
DCP-001C	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001B	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001A	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Pharm ML28897/PRO 02	Solid Tumors Other	Open Active	2019-07-16	Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
DCP-001D	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********

UNM - CRTC

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-03	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG Oncology NRG-BN003	Brain Other	Open Active	2017-10-20	NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
NCCTG N0577	Brain Advanced	Open Active	2017-12-18	NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Pharm LNS-101	Advanced Solid Tumors	Open Active	2019-10-11	Linnaeus Therapeutics LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer
Alliance A221505	Breast Advanced	Open Active	2018-04-10	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance A171601	Breast Advanced	Open Active	2020-01-03	Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-01-31	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2016-08-01	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Pharm RAD1901-308	Breast Advanced	Open Active	2019-12-06	Radius Pharmaceuticals RAD1901-308: Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial
Novartis CBYL719X2402	Breast Advanced	Open Active	2017-11-08	Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, NoncomparativeStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807	Breast Advanced	Open Active	2019-10-24	INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-03-28	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1706	Breast Neoadjuvant	Open Active	2019-06-24	SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-09-05	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Pharm WO40181	Breast Advanced	Open Active	2018-10-25	Genentech WO40181: A Phase II, Multicenter, Randomized Study to Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer who Experienced Disease Recurrence or Progression During or After CDK4/6 Inhibitor Therapy
Pharm SGNLVA-002	Breast Advanced	Open Active	2018-02-20	Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Pharm SGNLVA-001	Breast Advanced	Open Active	2017-09-26	Seattle Genetics, Inc. SGNLVA-001: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-LIVIA in Patients with LIV-1-Positive Metastatic Breast Cancer
Alliance A231701CD	CCDR	Open Active	2019-12-11	Alliance A231701CD: Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making through a Shared Decision Making Intervention
UNM 1525	Breast Prevention	Open Active	2016-09-22	INST UNM 1525: Breast cancer screening among medically underserved women in New Mexico: Comparing outcomes and LOwering recall rates with digital breast tomosynthesis (3D mammography) VErsus full-field digital (2D) mammography. The LOVE New Mexico study)
ECOG-ACRIN EA1151	Breast Other	Open Active	2018-08-31	ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2018-02-07	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
UNM 1607	Breast Neoadjuvant	Open Active	2018-04-16	INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI)
UNM 1528	Epidemiological	Open Active	2016-04-01	INST UNM 1528: Improving Colorectal Cancer Screening Rates in New Mexico Hispanics through Community Partnerships and Implementation Science
INST 1311	Epidemiological	Open Active	2013-02-04	INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation
CIBMTR Protocol for a Research Database	Epidemiological	Open Active	2017-06-29	CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
WFU WF-30917CD	CCDR	Open Active	2018-10-19	WFU WF-30917CD: A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
SWOG S1415CD	CCDR	Open Active	2017-06-07	SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
SWOG S0820	GI Colorectal Prevention	Open Active	2017-10-05	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
INST UNM 1809	GI Colorectal Prevention	Open Active	2018-12-27	INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
NRG Oncology/SWOG NRG-GI004/SWOG-S1610	GI Colorectal Advanced	Open Active	2019-07-22	NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502	GI Colorectal Adjuvant	Open Active	2018-10-12	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
UNM TCCP	Epidemiological	Open Active	2017-12-08	INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
UNM 1803	Epidemiological	Open Active	2018-06-26	INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
INST 1009	GI Other	Open Active	2010-11-17	INST 1009: The Link Between Chronic Inflammation and Gastrointestinal Cancers (HTR Study)
ECOG-ACRIN EA2165	GI Other	Open Active	2019-04-08	ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Alliance A021602	GI Other	Open Active	2019-05-08	Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Pharm XL184-312	GI Hepatic Advanced	Open Active	2019-10-31	Exelixis XL184-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Pharm 937-00	GI Hepatic Adjuvant	Open Active	2020-02-04	Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Pharm 866-00	GU Other	Open Active	2019-11-04	Merck 866-00: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
Pharm PANC003	GI Pancreatic Advanced	Open Active	2019-06-19	Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
UNM 1603	GI Other	Open Active	2016-11-30	INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
SWOG S1815	GI Other	Open Active	2019-04-05	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
INST Dana-Farber Cancer Institute 18-128	GI Other	Open Active	2019-07-15	INST Dana-Farber Cancer Institute 18-128: EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options - RCT of Usual Chemotherapy Educational Tools versus Investigational Chemotherapy Educational Tools
Pharm PrTK03	GU Prostate Adjuvant	Open Active	2017-06-28	Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
UNM 1805	GU Other	Open Active	2019-01-08	INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
Pharm CA209901	GU Other	Open Active	2019-06-11	Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Pharm 905-00	GU Other	Open Active	2020-02-04	Merck 905-00: A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer (KEYNOTE-905)
Alliance A031704	GU Renal Cell Advanced	Open Active	2019-11-26	Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE)
Pharm 1205-201	GU Prostate Advanced	Open Active	2018-08-01	Constellation Pharmaceuticals 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Pharm 010-00	GU Prostate Advanced	Open Active	2020-02-10	Merck 010-00: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
NRG Oncology NRG-GU005	GU Prostate Advanced	Open Active	2018-01-29	NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NRG Oncology NRG-GY006	GYN Cervical Advanced	Open Active	2020-02-18	NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
RTOG 0724/GOG-0724	GYN Cervical Adjuvant	Open Active	2015-07-23	RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263	GYN Cervical Adjuvant	Open Active	2010-10-20	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
UNM 1509	GYN Other	Open Active	2015-12-02	INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG Oncology NRG-GY005	GYN Other	Open Active	2019-06-24	NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Pharm 4010-03-001	GYN Endometrial Advanced	Open Active	2020-02-12	Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
NRG-GY018	GYN Endometrial Advanced	Open Active	2019-11-13	NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Pharm C-750-01/GOG-3028	GYN Cervical Advanced	Open Active	2019-11-14	Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
UNM 1419	GYN Ovarian Advanced	Open Active	2018-11-12	INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
Pharm 3000-02-006	GYN Ovarian Advanced	Open Active	2020-02-06	Tesaro 3000-02-006: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
NRG-GY021	GYN Ovarian Advanced	Open Active	2020-01-28	NRG-GY021: A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
NRG Oncology NRG-GY007	GYN Ovarian Advanced	Open Active	2018-12-17	NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-0264	GYN Ovarian Advanced	Open Active	2011-04-21	GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG 0238	GYN Uterine Advanced	Open Active	2015-08-24	GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
VBL Therapeutics VB-111-701/GOG 3018	GYN Ovarian Advanced	Open Active	2019-08-29	VBL Therapeutics VB-111-701/GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
INST 1310	Head And Neck Advanced	Open Active	2015-02-25	INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
ECOG-ACRIN EA3161	Head And Neck Advanced	Open Active	2020-02-06	ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
ECOG-ACRIN EA3132	Head And Neck Adjuvant	Open Active	2016-12-14	ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
SWOG S1712	Hematology Chronic Leukemia	Open Active	2019-02-21	SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Alliance A041702	Hematology Chronic Leukemia	Open Active	2019-06-14	Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
UNM 1512	Hematology Acute Leukemia	Open Active	2018-05-23	INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
INST 0551C	Hematology Acute Leukemia	Open Active	2016-05-02	INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia
NRG Oncology NRG-HN004	Head And Neck Advanced	Open Active	2019-03-20	NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
ECOG-ACRIN NHLBI-MDS	Hematology Other	Open Active	2016-10-06	ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
Alliance A061202	Hematology Myeloma	Open Active	2018-10-03	Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
SWOG S1608	Hematology Lymphoma Non-Hodgkins	Open Active	2019-12-16	SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SWOG S1803	Hematology Myeloma	Open Active	2019-11-14	SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
INST 1306	Ill Defined	Open Active	2015-01-01	INST 1306: Whole Genome Sequencing of Human Cancer Tissues
Pharm INCB 18424-MA-GD-301	Hematology Stem Cell Transplant	Open Active	2019-01-29	Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
UNM 1709	Ill Defined	Open Active	2019-05-30	INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-03-14	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-03-14	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-05-09	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105	Lung NSCLC Adjuvant	Open Active	2019-11-12	Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A091802	Skin Melanoma Advanced	Open Active	2019-12-06	Alliance A091802: Phase II Randomized Trial of Avelumab Plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
SWOG S1400F	Lung SCLC Advanced	Open Active	2019-11-06	SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
NRG-LU005	Lung SCLC Adjuvant	Open Active	2020-02-05	NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
NRG Oncology NRG-CC003	Lung SCLC Adjuvant	Open Active	2019-01-09	NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
SWOG S1801	Skin Melanoma Advanced	Open Active	2019-06-27	SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
SWOG S1616	Skin Melanoma Advanced	Open Active	2019-07-02	SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Pharm 2455-001	Solid Tumors Other	Open Active	2018-03-06	Kyowa Kirin Pharmaceutical 2455-001: Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Alliance A011401	Supportive	Open Active	2016-10-02	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Pharm SGNS40-001	Solid Tumors Other	Open Active	2019-12-18	Seattle Genetics SGNS40-001: A Phase I, Open-label Dose Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Alliance Foundation Trials AFT-28	Supportive	Open Active	2018-09-12	Alliance Foundation Trials AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Pharm R3767-ONC-1613	Solid Tumors Other	Open Active	2017-12-15	Regeneron Pharmaceuticals R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
Pharm ML28897/PRO 02	Solid Tumors Other	Open Active	2019-07-03	Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
DCP-001B	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001C	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001D	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001A	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-002	Supportive	Open Active	2017-11-16	NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
INST Johns Hopkins Hospital 1802	Supportive	Open Active	2019-09-20	INST Johns Hopkins Hospital 1802: A Multi-Center Randomized Control Trial of Perioperative Palliative Care Surrounding Surgery for Patients and Their Family Members
NRG Oncology NRG-CC004	Supportive	Open Active	2017-10-12	NRG Oncology NRG-CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
WFU WF 97115	Supportive	Open Active	2017-07-06	WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
ECOG-ACRIN E1Q11	Supportive	Open Active	2018-04-18	ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
WFU WF-1801	Supportive	Open Active	2019-09-27	Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy